The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Treatment approaches for patients with TP53m AML ineligible for high intensity chemotherapy
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, discusses treatment options for patients with TP53 mutated acute myeloid leukemia (AML) who are ineligible for high intensity chemotherapy. Prof. Konopleva emphasizes the value of enrolling these patients in clinical trials and further comments on the promising data emerging with magrolimab. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
